A novel approach to matching patients with pancreatic ductal adenocarcinoma (PDAC) to effective chemotherapy has shown significant promise. Patient-derived organoids (PDOs) matched 91% of patients to standard treatments, improving CA 19-9 markers and lymph node staging. Notably, those who received therapies well-aligned with their PDO chemosensitivity experienced better recurrence-free and overall survival compared to misaligned treatments. These findings suggest that PDO pharmacotyping may optimize therapeutic strategies and improve patient quality of life.
Journal Article by Nicolson NG, Tandurella JA (…) Burkhart RA et 14 al. in Ann Surg
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.